Microenvironment interactions in Chronic Lymphocytic Leukemia a Delicate Equilibrium Linking The Quiescent and The Proliferative Pool

B-cell Chronic Lymphocytic Leukemia (cll) Is Considered A Single Disease With Extremely Variable Course, And Survival Rates Ranging From Months To Decades. It Is Clear That Clinical Heterogeneity Reflects Biologic Diversity With At Least Two Major Subtypes In Terms Of Cellular Proliferation, Clinical Aggressiveness And Prognosis. As Cll Progresses, Abnormal Hematopoiesis Results In Pancitopenia And Decreased Immunoglobulin Production, Followed By Nonspecific Symptoms Such As Fatigue Or Malaise. A Cure Is Usually Not Possible, And Delayed Treatment (until Symptoms Develop) Is Aimed At Lengthening Life And Decreasing Symptoms. Researchers Are Playing A Lead Role In Investigating Cll's Cause And The Role Of Genetics In The Pathogenesis Of This Disorder. Research Programs Are Dedicated Towards Understanding The Basic Mechanisms Underlying Cll With The Hope Of Improving Treatment Options. 00_preface_Chronic Lymphocytic Leukemia......Page 1 00x_part1......Page 15 01_Selected Topics in Chronic Lymphocytic Leukemia Pathogenesis......Page 17 01x_part2......Page 33 02_Microenvironment Interactions in Chronic Lymphocytic Leukemia: A Delicate Equilibrium Linking the Quiescent and the Proliferative Pool......Page 35 03_Dysregulation of Apoptosis and Proliferation in CLL Cells......Page 51 04_DNA Damage Response/Signaling and Genome (In)Stability as the New Reliable Biological Parameters Defining Clinical Feature of CLL......Page 77 05_Current Knowledge of Microarray Analysis for Gene Expression Profiling in Chronic Lymphocytic Leukemia......Page 109 06_Contribution of microRNAs to CLL Biology and Their Potential as New Biomarkers......Page 133 07_The Biological Relevance of ZAP-70 in CLL......Page 149 08_Pathophysiology of Protein Kinase C Isozymes in Chronic Lymphocytic Leukaemia......Page 167 09_The Role of Polymorphisms in Co-Signalling Molecules’ Genes in Susceptibility to B-Cell Chronic Lymphocytic Leukaemia......Page 193 09x_part3......Page 215 10_Mouse Models of Chronic Lymphocytic Leukemia......Page 217 11_Altering microRNA miR15a/16 Levels as Potential Therapy in CLL: Extrapolating from the De Novo NZB Mouse Model......Page 243 11x_part4......Page 263 12_Prognostic Factors in Chronic Lymphoid Leukemia and Identification of New Clinically Relevant Molecular Markers......Page 265 13_Genetics of Chronic Lymphocytic Leukemia: Practical Aspects and Prognostic Significance......Page 283 13x_part5......Page 311 14_Immune Response and Immunotherapy in Chronic Lymphocytic Leukemia......Page 313 15_In Vitro Sensitivity Testing in the Assessment of Anti-CLL Drug Candidates......Page 337 16_Interactions of the Platinum(II) Complexes with Nitrogen- and Sulfur-Bonding Bio-Molecules in Chronic Lymphocytic Leukemia......Page 353 17_Infectious Diseases and Clinical Complications During Treatment in CLL......Page 381 18_Emerging Therapies in Chronic Lymphocytic Leukemia......Page 397 19_Heat Shock Proteins in Chronic Lymphocytic Leukaemia......Page 413 20_Present and Future Application of Nanoparticle Based Therapies in B-Chronic Lymphocytic Leukemia (B-CLL)......Page 445